CELU
Placental Derived Cell Type Program Indication Preclinical IND Submission Phase I Phase II ONCOLOGY Unmodified Natural Killer Cell CYNK-001 Acute Myeloid Leukemia(AML) Genetically Modified Natural Killer Cell CYNK-101 +m
Wednesday, March 16, 2022 1 min read
Key Takeaway: Placental Derived Cell Type Program Indication Preclinical IND Submission Phase I Phase II ONCOLOGY Unmodified
Natural Killer Cell CYNK-001 Acute Myeloid Leukemia(AML) Genetically Modified Natural Killer Cell CYNK-101 +mAb Glioblastoma Multiforme (GBM) HER+ Gastric Cancer CAR-T
Full Press Release Details
Placental Derived Cell Type Program Indication Preclinical IND Submission Phase I Phase II ONCOLOGY Unmodified
Natural Killer Cell CYNK-001 Acute Myeloid Leukemia(AML) Genetically Modified Natural Killer Cell CYNK-101 +mAb Glioblastoma Multiforme (GBM) HER+ Gastric Cancer CAR-T CYCART-19* B-Cell Malignancies DEGENERATIVE DISEASES Placental Mesenchymal-like
Stomal Cells APPL 001 Crohn s Disease PDA-002 Facioscapulohumeral Muscular Dystrophy (FSHD) *includes technology in-licensed from Sorrento Therapeutics, Inc.